一项研究发现,针对40纳克/毫升以上水平的高剂量维生素D3在心脏病患者中将重复性心脏病发作的风险降低52%。 High-dose vitamin D3, targeting levels above 40 ng/mL, cut repeat heart attack risk by 52% in heart patients, a study found.

Intermountain Health的一项大型研究发现,通过个性化补充,针对40纳克/毫升以上维生素D3水平,使前心脏病患者第二次心脏病发作的风险降低52%。 A large study by Intermountain Health found that targeting vitamin D3 levels above 40 ng/mL through personalized supplementation reduced the risk of a second heart attack by 52% in patients with prior heart disease. 从2017年到2025年,TARGET-D试验在630名病人之后进行,大多数病人开始时的剂量不足,需要高剂量——通常每天超过5 000个IU——才能达到目标。 The TARGET-D trial followed 630 patients from 2017 to 2025, with most starting with insufficient levels and needing high doses—often over 5,000 IU daily—to reach targets. 与以往使用固定剂量的试验不同,这种方法对剂量水平进行监测,并定期调整剂量,没有任何安全关切。 Unlike past trials using fixed doses, this approach monitored levels and adjusted dosing regularly, showing no safety concerns. 虽然总体而言,主要心脏病事件没有显著变化,但重复心脏病发作次数的减少是持续和显著的。 While no significant change was seen in overall major cardiac events, the reduction in repeat heart attacks was consistent and notable. 成果已提交美国心脏协会2025年科学会议,等待同侪审查。 Results were presented at the American Heart Association Scientific Sessions 2025 and await peer review.